E. Ohman J:Or Asset Management Ab Biocryst Pharmaceuticals Inc Transaction History

E. Ohman J:Or Asset Management Ab

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 05, 2024	SELL	$7.94 - $11.84 $1.16 Million - $1.73 Million	-145,921 Closed	0 $0
Q4 2022 Apr 05, 2024	BUY	$10.5 - $14.2 $516,148 - $698,029	49,157 Added 50.8%	145,921 $1.68 Billion
Q3 2022 Apr 05, 2024	SELL	$10.79 - $14.81 $561,026 - $770,045	-51,995 Reduced 34.95%	96,764 $1.22 Billion
Q2 2022 Apr 05, 2024	BUY	$7.89 - $17.88 $394,500 - $894,000	50,000 Added 50.63%	148,759 $1.57 Billion
Q1 2022 Apr 05, 2024	SELL	$11.56 - $19.76 $995,789 - $1.7 Million	-86,141 Reduced 46.59%	98,759 $1.61 Billion
Q4 2021 Apr 05, 2024	BUY	$11.18 - $15.46 $601,484 - $831,748	53,800 Added 41.04%	184,900 $2.56 Billion
Q3 2021 Apr 05, 2024	BUY	$14.21 - $17.65 $99,470 - $123,549	7,000 Added 5.64%	131,100 $1.88 Billion
Q2 2021 Apr 05, 2024	SELL	$9.5 - $17.24 $190,000 - $344,799	-20,000 Reduced 13.88%	124,100 $1.96 Billion
Q1 2021 Apr 05, 2024	BUY	$7.37 - $13.61 $117,920 - $217,760	16,000 Added 12.49%	144,100 $1.47 Billion
Q4 2020 Apr 05, 2024	BUY	$3.37 - $8.61 $431,697 - $1.1 Million	128,100 New	128,100 $954 Million

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.